Merck的股票在收入损失和决定停止向中国运送Gardasil之后下跌。 Merck's stock drops after earnings miss and decision to halt Gardasil shipments to China.

Merck & Co.提供了25财政年度收入指导,EPS为8.88-9.03美元,收入为641-656亿美元,缺少分析师估计数。 Merck & Co. provided FY25 earnings guidance with EPS of $8.88-$9.03 and revenue of $64.1-$65.6 billion, missing analyst estimates. 由于指导不力,决定停止向中国运送Gardasil公司的货物,以解决库存过剩问题,从而影响销售预测,因此该公司的股票下降。 The company's stock fell due to weak guidance and a decision to halt Gardasil shipments to China to address excess inventory, impacting sales forecasts. 尽管存在这些问题,Merck报告第四季度销售额增加了7%,Keytruda销售额增加了19%。 Despite these issues, Merck reported a 7% increase in fourth-quarter sales and a 19% rise in Keytruda sales. 该公司还宣布了一项100亿美元的股票回购计划和每股0.81美元的季度红利。 The company also announced a $10 billion stock buyback plan and a quarterly dividend of $0.81 per share.